KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
WALTHAM, Mass., Sept. 05, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Morgan Stanley Annual Global Health Care Conference
Monday, September 11, 2017 at 3:40 p.m. ET
Location: New York, NY - Cantor Fitzgerald Global Healthcare Conference
Wednesday, September 27, 2017 at 2:50 p.m. ET
Location: New York, NY - Deutsche Bank Leveraged Finance Conference
Wednesday, October 4, 2017 at 3:35 p.m. MT (6:35 p.m. ET)
Location: Scottsdale, AZ
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
